Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.

Australian respiratory technology company Rhinomed Ltd (ASX:RNO) has struck an important sales agreement with global sleep technology heavyweight ResMed Inc (NYSE:RMD) (ASX:RMD) to begin selling the novel Mute(TM) snoring reduction and sleep technology in the key UK market.

Compumedics Limited (ASX:CMP) is pleased to announce it has secured a new $1.0 million (USD 0.75 million) contract to supply a major US-based hospital group with its Grael(TM) and Neuvo(R) EEG neurology systems.

Compumedics Limited (ASX:CMP) Up-dated May 2015 Corporate Presentation including an Investor overview.

Rhinomed (ASX:RNO) is pleased to announce it has continued to expand its Australian wholesale pharmacy distribution footprint with Sigma Pharmaceuticals Limited (ASX:SIP) to wholesale its Mute™ snoring and sleep quality technology.

Compumedics Limited (ASX:CMP) announce the Broker Presentation for May 2015 with significant highlights.

Compumedics Limited (ASX:CMP) is pleased to announce that it has secured a new three-year contract, for the distribution of Compumedics' neurological monitoring systems across provinces in South East China.

Compumedics Limited (ASX:CMP) is pleased to announce that the Company's Germany-based, brain blood-flow Doppler-sonography division, Compumedics Germany GmbH, has been awarded a new European patent for a new approach to ultrasound diagnosis and treatment of stroke.

Compumedics Limited (ASX:CMP) is pleased to announce that the Company's German-­-based, brain blood-­-flow Doppler-sonography division, Compumedics Germany GmbH, has secured a AUD$375K deal to supply its Doppler-Box technology to key military hospitals in China.

Leading Australia-based medical device company, Compumedics Limited (ASX:CMP) is pleased to announce profitability and revenue growth for the half year ending 31 December 2014.